RecruitingPhase 2NCT05635344
A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia
Studying Gestational trophoblastic disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Imperial College London
- Principal Investigator
- Ehsan GhoraniImperial College London University
- Intervention
- Pembrolizumab(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2024 – 2026
Study locations (1)
- Imperial College Healthcare NHS Trust, London, United Kingdom
Collaborators
Cancer Research UK
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05635344 on ClinicalTrials.govOther trials for Gestational trophoblastic disease
Additional recruiting or active studies for the same condition.